Market research
EXK.F Exact Sciences Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 17B
- P/E ratio
- Not available
- Analyst target
- 148.88
- Dividend yield
- Not available
- Beta
- 1.44
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US30063P1057
- Market cap
- 17B
- P/E ratio
- Not available
- Analyst target
- 148.88
- Dividend yield
- Not available
- Beta
- 1.44
About
About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. As of March 23, 2026, Exact Sciences Corporation operates as a subsidiary of Abbott Laboratories.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EXK.F discussion.
5 years, 4 months ago
Exact Sciences Corporation is currently in a long term downtrend where the price is trading 5.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.7.
Exact Sciences Corporation's total revenue rose by 57.8% to $466M since the same quarter in the previous year.
Its net income has dropped by 660.4% to $-437M since the same quarter in the previous year.
Finally, its free cash flow grew by 237.5% to $95M since the same quarter in the previous year.
Based on the above factors, Exact Sciences Corporation gets an overall score of 3/5.